A B S T R A C T The mechanism of protection of typespecific antipneumococcal antibody and complement in bacteremia was investigated with purified rabbit antibody and a guinea pig model of pneumococcal bacteremia. IgG and IgM were isolated from the sera of rabbits immunized with type 7 pneumococci (Pn), and their binding to Pn was quantitated. The number of antibody-binding sites on the pneumococcal capsule was also determined. Pn were incubated with various amounts of the immunoglobulin preparations before intravenous injection into nonimmune guinea pigs. Whereas 120 molecules of IgM per Pn were sufficient to enhance bloodstream clearance of Pn, 1,400 molecules of IgG per bacterium were required to produce this effect. As the amount of either IgG or IgM added to the Pn was increased, the rate of bloodstream clearance accelerated. In striking contrast, >1,000 molecules of IgM had no effect on the rate of clearance in C4-deficient guinea pigs, which cannot activate complement via the classic pathway. Similarly, 5,000 molecules of IgG had only minimal effect in C4-deficient guinea pigs, and 24,000 molecules of IgG had no effect in guinea pigs depleted of complement by cobra venom factor. Thus, the in vivo opsonic effects of both IgG and IgM anticapsular antibody are mediated via their ability to activate complement.
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IgG anti-pneumococcal cell wall antibody, raised by intravenous injection of rabbits with unencapsulated Pn, had no effect on the rate of bloodstream clearance of Pn or on the polymorphonuclear leukocyte killing of type 7 Pn in an in vitro bacterial assay. Because the opsonic effects of anticapsular antibody required complement activation, the ability of anticell wall IgG to activate complement was compared with the two classes of anticapsular antibody. As judged by depletion of C3 and C4 from guinea pig serum, as well as by the fixation of radiolabeled C3 to Pn, IgM anticapsular antibody was the best complement activator. However, anticell wall IgG was somewhat more active than anticapsular IgG in each of these tests of complement activation and fixation. When equivalent amounts of C3 were fixed to Pn by each of the three antibodies, Pn sensitized with IgG and IgM anticapsular antibodies caused immune adherence, whereas Pn sensitized with anticell wall IgG did not. This may explain the failure of anticell wall antibody to mediate complement-dependent phagocytosis of Pn in vivo or in vitro. Although anticell wall IgG is capable of activating complement and fixing CS to Pn, it is not opsonic; the most likely reason is that the nonopsonic antibody mediates C3 deposition in sites on the Pn that cannot interact efficiently with phagocytic cell C3 receptors.
INTRODUCTION
In 1897 Bezanqon and Griffon (1) recognized serologic differences among pneumococci (Pn)' which later were correlated with differences in the specific soluble substance, or polysaccharide capsule, by Avery and Heidelberger (2). These differences assumed major clinical significance when it was recognized that infection with one type of Pn did not necessarily confer protection against infection by other pneumococcal types and, in the era of serum therapy, that only serum that contained antibody directed against the type-specific polysaccharide of the infecting organism was of therapeutic benefit (3, 4) . It was also recognized at that time that antibodies could be induced by injection of rabbits with unencapsulated Pn or with pneumococcal cell wall lysates that reacted with the cell walls of all types of Pn (5, 6) . With few exceptions (6, 7) the evidence from experimental systems using animal models of pneumococcal disease has been that this antibody plays at most a small role in resistance to infection by encapsulated organisms (8) . The reasons for these important differences in efficacy between type-specific anticapsular antibody, which were easily shown to be opsonic (9) and these broadly reactive antibodies have not been carefully explored. For example, most studies of the biologic effects of antipneumococcal antibody (10, 11) were done before different antibody classes were distinguished, before the mechanisms of interaction of antibodies with complement were understood, and before the ability of Pn to activate complement without the mediation of antibody, via the alternative pathway, was discovered. More recent studies of the requirements for phagocytosis have often investigated particles other than Pn and have differed as to whether complement alone or antibody alone is a sufficient signal for phagocytosis (12, 13) .
We have developed an in vivo model for the study of phagocytosis of Pn by the fixed macrophages of the reticuloendothelial system (RES) (14, 15 (17) .
75Se-Pn. Log-phase Pn were radiolabeled in a completely defined artificial medium (18) that contained [75Se]methionine (Amersham Ltd; Arlington Heights, Ill.) as the only source of methionine, as previously described (15) . In brief, 2-h cultures of Pn were grown for 90 min in 40 ml of the medium containing 40 sCi of [75Se]methionine, washed twice in icecold PBS, pH 7.4, and used within 1 h.
Guinea pigs. Normal (National Institutes of Health; NIH-GP) or C4-deficient (C4D-GP) (19) 300-400 g female guinea pigs were obtained from colonies maintained by the National Institutes of Health. Blood was obtained from guinea pigs via cardiac puncture and was separated after 1 h at room temperature. The serum was stored in aliquots at -70°C until used. This nonimmune serum had no detectable antitype 7 antibody as determined by enzyme-linked immunoabsorbent assay, performed as previously described (20) .
In vivo complement depletion. Cobra venom factor, partially purified venom of Naja naja (Cordis Laboratories Inc., Miami, Fla.), was used to deplete alternative-and late-pathway-complement components by intravenous injection into guinea pigs as previously described (14) . With this regimen, hemolytic C3 titers in these guinea pigs, as measured by standard methods, were 0.1-1% of normal at the time of induction of bacteremia (Cobra venom-treated guinea pigs; CVF-GP).
Antipneumococcal antibody. Rabbits were immunized with heat-killed formalinized Pn, either type 7 or R36a, according to the schedule of the Massachusetts Antitoxin and Vaccine Laboratory, Boston, Mass. (21). 4-10 wk after the beginning of immunization the production of antibody was assessed by the ability of dilutions of rabbit serum to agglutinate homologous Pn. Sera with the highest titers were selected for further purification. Rabbit sera were not pooled for purification. 15-25 ml of rabbit serum was mixed with saturated ammonium sulfate in the cold to give a final concentration of 30% (NH4)2SO4. The precipitate was resuspended in a minimal volume of PBS, pH 7.4, and applied to a 1,500-ml bed volume Biogel A 0.5-m column (Bio-Rad Laboratories, Richmond, Calif.). The resultant peaks were then collected, concentrated, and sedimented in a 10-30% sucrose gradient for 16 h at 100,000 g (SW-41 rotor, Beckman Instruments Inc., Spinco Div., Irvine, Calif.). These highly purified IgG and IgM fractions were then stored at 4°C until used. Aliquots of these IgG and IgM pools were radiolabeled with '25I by the Bolton-Hunter reagent as previously described (22 Thereafter, the sensitized Pn were kept on ice until injection, always within 30 min. Quantitative cultures of these suspensions were made before and after these incubations to ensure that there was no toxic effect of the antibody solution and that the room temperature incubation did not lead to a nonspecific loss of viability. There was no difference in colony counts between Pn suspensions before and after incubation or between those incubated with antibody and with PBS alone. The rate of removal of these sensitized Pn from the bloodstream of guinea pigs after intravenous injection was determined by serial bleeding from the retroorbital plexus at prescribed times after injection, as previously described (14, 20) . Clearance studies were performed with two or three animals at each level of antibody sensitization. An equal number of control animals received unsensitized Pn in each experiment.
Localization in NIH-GP. Studies of localization of NIH-GP were performed as previously described (20) by killing guinea pigs 45 min after the injection of 108-109 75Se-Pn, preincubated with antibody diluted in PBS or with PBS alone as a control. Whole-organ radioactivity counts were made of liver, spleen, and lung. An aliquot (0.2 ml) of whole blood was also counted (Gamma 310 Radiation Counter, Beckman Instruments), and the radioactivity remaining in blood was calculated by assuming a blood volume equal to 7% of the body weight. This figure had been determined from the injection of 51Cr-labeled, unsensitized guinea pig E. Detailed studies of bloodstream clearance and localization kinetics have been reported (20, 21) . In brief, there is an early exponential removal of Pn from the blood that continues for [2] [3] [4] h. In the first 5 min after injection as many as 25% of the Pn are localized in the pulmonary circulation, but this phase of clearance is over by 30 min. Thus, for the localization experiments reported here, 45 min was chosen as a time at which log-phase clearance was still progressing, dilution of radiolabel by division of microorganisms was minimal, and the radiolabeled organisms had not been destroyed and released from the RES by phagocytic cell lysosomal activity. Preliminary studies showed that the relative ratio of hepatic to splenic sequestration is maintained throughout the exponential phase of clearance.
Bactericidal assay. Type 7 Pn from a 4-h broth culture were washed two times in HBSS and resuspended to 1 x 108/ ml in HBSS. Polymorphonuclear leukocytes (PMN) were obtained from peripheral blood by dextran sedimentation and Hypaque-Ficoll density gradient centrifugation as previously described (24) . 1 ml of a reaction mixture was made that contained 1 X 107 Pn, 0.1 ml fresh normal human serum that had low titers of antibody to type 7 polysaccharide determined by enzyme-linked immunoabsorbent assay as previously described (25) To examine the ability of the IgG and IgM antibodies to support the assembly of a classic-pathway C3 convertase from purified guinea pig complement components, the following studies were carried out. 5 X 107 type 7 Pn sensitized as described above were washed, resuspended in 0.5 ml GVBD, incubated with 1,000 U of Cl (Cordis Laboratories) for 15 min at 30°C, washed in GVBD at room temperature, and resuspended in GVBD as described above. These Pn were then incubated with 100 U of C4 (Cordis Laboratories) for 30 min at 370C, washed in GVBD at 4°C, and finally resuspended in GVBD. 100 U C2 (Cordis Laboratories) was then added to these Pn. The mixture was incubated for 10 min at 30'C, and 3.5 Mg 125I-C3 was then added. The bacteria were then incubated with the complement components for 1 h at 370C and washed on albumin-coated Millipore filters as described above. All experiments were performed on at least two occasions and in duplicate on each occasion. Controls included determination of CS uptake on unsensitized Pn and antibody-sensitized Pn that had been incubated with GVBD instead of Cl or C2. Uptake in control tubes in these experiments was always <1.5% of C3 input.
Immune adherence. 5 X 107 Pn were sensitized with 5,000 molecules/CFU of IgG anti-type 7, 5,000 molecules of IgG anti-cell wall, or 1,000 molecules/CFU of IgM antitype 7. Pn were then incubated as described above with purified Cl, C4, C2, and C3. The number of C3b molecules/ CFU was determined from the net uptake of radiolabeled C3. 1.5 X 107 of such antibody-and complement-sensitized Pn, suspended in 40 ul GVBD, were incubated in microtiter plates with 25 Ml of washed fresh human type 0, Rh positive E suspended to 6.5 X 107 E/ml in GVBD. These suspensions were incubated at 37°C for 15 min, and agglutination patterns were quantitated as previously described (16) .
Statistical methods. Hepatic and splenic localization data and geometric means of blood colony counts were compared by a two-tailed Student's t test. Data are expressed as mean±SEM.
RESULTS
Binding of anticapsular IgG and IgM to Pn. A maximum of 3.5% of the radiolabeled IgG preparation bound to type 7 Pn. 1% of this antibody preparation bound to rough Pn, and negligible amounts (<0.1%) bound to unrelated organisms (Fig. 1) Calculation of IgG binding sites on the pneumococcal capsule. Inasmuch as the total number of anticapsular antibody molecules per microgram of the total IgG preparation was now known, calculation of the available antibody-binding sites was possible. Increasing amounts of radiolabeled antibody were added to 106, 5 X 106, or 107 Pn, and the uptake of radiolabel was determined in the presence and absence of a 20-fold excess of unlabeled antibody. Binding to unrelated organisms was also used as a control for nonspecific uptake of radiolabel. Scatchard plots of this data led to a calculation of 150,000 binding sites/CFU (Fig.  3A) . By the use of Scatchard analysis, the total number of IgG binding sites present in the whole pneumococcal pool was determined at each of the three concentrations of organisms. When these numbers were plotted vs. the total number of organisms present, the slope of the line also indicated 150,000 IgG binding sites/ CFU (Fig. 3B) (Fig. 4) ance (Table I ). There was no difference between the sequestration patterns of unsensitized Pn and Pn sensitized with 500 molecules IgG/CFU. However, there was a significant increase in the hepatic sequestration of Pn incubated with enough antibody to give 3,000 IgC/CFU (P < 0.01). Splenic sequestration in these animals was less than that in animals injected with unsensitized Pn, but the difference did not reach statistical significance.
Clearance of IgG-sensitized Pn in C4D-GP and CVF-GP. The clearance of Pn sensitized with anticapsular IgG was compared with unsensitized Pn in C4D-GP, in which complement can be activated only via the alternative pathway. In these animals, 5 ,000 molecules of IgG/CFU, which causes nearly maximal clearance rates in NIH-GP, caused a slight, statistically significant increase in the rate of clearance (Fig. 6A) . However, the rate of clearance of these Pn sensitized with 5,000 IgG/CFU in C4D-GP was not as fast as the rate of clearance of even unsensitized Pn in NIH-GP. In CVF-GP, which are depleted of alternative pathway components and C3-C9, Pn sensitized with 24,000 IgG molecules/CFU were cleared with kinetics no different from the clearance of unsensitized Pn in CVF-GP and markedly slower than the clearance of unsensitized Pn in NIH-GP (Fig. 6B) .
Clearance of IgM-sensitized Pn. The kinetics of clearance of Pn preincubated with PBS or various amounts of IgM is shown in Fig. 7A . In complementsufficient NIH-GP as few as 120 molecules of IgM/ CFU caused a statistically significant increase in the rate of pneumococcal clearance. There was a dose-dependent increase in clearance rates as with IgG. 500 molecules/CFU caused nearly maximal clearance rates, since the rate of clearance of Pn sensitized with 5,000 molecules of IgM/CFU was not different from that of Pn sensitized with 500 molecules of IgM/CFU (data not shown). The ability of IgM to enhance pneumococcal clearance was entirely dependent on activation of the classic pathway of complement, as shown by clearance kinetics in C4D-GP. In these guinea pigs >1,000 molecules of IgM/CFU had no effect on clear- ance rates (Fig. 7B) . Localization studies performed with 300 molecules of IgM/CFU showed that IgM, like IgG, mediated increased hepatic sequestration of Pn (Table I) . Clearance studies with anticell wall antibody. Anticell wall IgG was incubated with type 7 Pn to provide 1,600, 3,200, 15,000, 30,000, and 44,000 molecules of IgG/CFU. No dose of anticell wall antibody caused a change in the rate of pneumococcal clearance from the bloodstream, compared with Pn incubated with PBS alone (Fig. 8) .
In vitro phagocytosis. The abilities of IgG anti-cell wall antibody and IgG and IgM anticapsular antibodies to enhance phagocytosis of pneumococci by human PMN were compared in an in vitro bactericidal assay. IgG and IgM anticapsular antibodies both were able to enhance complement-dependent pneumococcal killing by PMN in a dose-dependent fashion. However, anti-cell wall IgG had no effect on phagocytosis of pneumococci at any dose (Fig. 9) . Because IgG and IgM anticapsular antibodies were able to enhance both bloodstream clearance of Pn in the guinea pig model and phagocytosis in vitro, they were considered opsonic antibodies. Because anticell wall IgG was active in neither of these assays, it was considered nonopsonic.
Antibody-mediated depletion of complement from serum. We next tested whether the difference between the opsonic anticapsular antibodies and the nonopsonic anticell wall antibody lay in their ability to activate complement. For these experiments, Pn sensitized with various amounts of antibody were incubated with diluted GPS. The depletion of C4, a component of the classic pathway, was first examined. In nonimmune serum there was no detectable anticapsular antibody and no activation of the classic pathway was detectable without antibody sensitization. Hemolytic C4 titers of serum after incubation with unsensitized Pn were uio different from the titers of serum to which Pn had not been added. Sensitizing the Pn with increasing amounts of antibody led to increasing C4 depletion (Fig. 10) . Anticapsular IgM depleted C4 to the greatest extent. Surprisingly, IgG anticell wall antibody depleted C4 at least as well as anticapsular IgG in these experiments.
Next, the effect of the different antibody preparations on C3 depletion was examined. C3 can be activated via either the classic or the alternative pathway. Thus, a small amount of C3 depletion (10%) was observed after incubation of unsensitized Pn in 1% nonimmune serum. This is consistent with direct activation of the alternative pathway by the unsensitized Pn. Sensitization of Pn with antibody led to dose-dependent increases in C3 depletion (Fig. 11) . Again, IgM was most efficient at C3 activation. Anticell wall IgG depleted C3 to a greater extent than anticapsular IgG 9 The effects of anticapsular and anticell wall antibody on in vitro phagocytosis of Pn. The abilities of anticapsular IgG (0), anticapsular IgM (A), and anticell wall IgG (-) to enhance serum-dependent pneumococcal killing are compared. There is a dose-dependent increase in killing mediated by anticapsular IgG and IgM. IgG anticell wall has no effect on phagocytosis of Pn by PMN.
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DISCUSSION
In this study we examined and compared the effects of purified anticapsular IgG and IgM with anticell wall IgG on the clearance of Pn from the bloodstream of nonimmune guinea pigs. Immunization is known to protect both experimental animals and humans from pneumococcal infection because of the development of type-specific antibody (11, 34) , but the way in which antibody protects against in vivo challenge has been largely uninvestigated. The studies reported here suggest that opsonization of Pn with type-specific antibody, either IgG or IgM, requires the mediation of complement for in vivo efficacy. The evidence for this was provided by studies of the rates of clearance of intravenously injected, antibody-sensitized Pn in NIH-GP, which have normal complement pathways; in C4D-GP, which can activate complement only via the alternative pathway; and in CVF-GP, which are markedly deficient in C3, the primary opsonin of the complement system (35) . Even large amounts of IgM anticapsular antibody had no effect on clearance of Pn if activation of the classical pathway was blocked, as in C4D-GP. Although anticapsular IgG had some effect on the rate of pneumococcal clearance in C4D-GP, its opsonic capability was markedly diminished compared with its effect in NIH-GP. Even this small effect of IgG in C4D-GP required complement activation via the alternative pathway, since all effect of IgG was abolished in CVF-GP. Thus, antibody-mediated classical pathway activation is essential for the expression of any opsonic effect of type-specific IgM and for the maximum effect of anticapsular IgG. The small but significant effect of IgG antibody in C4D-GP provides some evidence that IgG but not IgM activates the alternative pathway. In its ability to enhance alternative pathway activation, anticapsular IgG is similar to a number of previously reported IgG antibodies (36, 37 The effects of IgG antibody on the clearance of Pn and GPE differ in several ways. First, antierythrocyte IgG antibody does not interact with the alternative pathway of complement activation, but anticapsular IgG probably does. Second, Pn sensitized with anticapsular IgG do not interact significantly with the splenic IgG receptor, since their clearance is not enhanced in the absence of complement; this is unlike the clearance of IgG-coated E, which are sequestered by the spleen at a slow rate in CVF-GP. Finally, anticapsular IgG mediates hepatic clearance of Pn, whereas IgG-sensitized GPE are sequestered by the spleen, except at very high levels of antibody sensitization.
We have also characterized a rabbit IgG antipneumococcal antibody that reacts with pneumococcal cell walls, and we have shown that it does not enhance either the bloodstream clearance of Pn in vivo or the killing of Pn by PMN in vitro. In this respect it is clearly different from both the IgG and the IgM antipneumococcal antibodies with specificity for the polysaccharide capsule. Because it does not affect the ability of either PMN or the fixed macrophages of the reticuloendothelial system to ingest Pn, we have called this anticell wall antibody nonopsonic.
In agreement with our findings, there are many studies in animals and humans that demonstrate that anticell wall antibodies are not opsonic (summarized in reference 3). Some investigators, however, have found antipneumococcal cell wall antibodies that confer protection in mice (40) (41) (42) . This discrepancy may have been resolved by Briles et al. (43) , who showed that monoclonal antiphosphorylcholine antibodies could protect mice against lethal infection by an encapsulated pneumococcus. Thus, the differences in opsonic effect between protective and nonprotective anticell wall antisera may relate to differences in the amounts of antiphosphorylcholine antibody they contain. Because the C-carbohydrate that contains the cell wall phosphorylcholine (44) is poorly immunogenic (45) , there is likely to be little antiphosphorylcholine antibody in most anticell wall preparations.
Because the opsonic effect of rabbit anticapsular antibody in vivo, whether IgM or IgG, depends on its ability to fix complement, we tested the hypothesis that the difference between opsonic and nonopsonic antibodies lies in their ability to activate complement. However, the experiments demonstrated that IgG anticell wall antibody was slightly more efficient than IgG anticapsular antibody, both in its ability to activate complement, as judged by the depletion of C4 and C3 in serum, and in its ability to deposit radiolabeled guinea pig C3 onto the pneumococcal surface. This was not an artifact of the use of dilute GPS, since anticell wall IgG also mediated C3 deposition on Pn as efficiently as anticapsular IgG in much more concentrated (10%) serum. Hence, the difference in opsonic effect between the anticapsular and anticell wall antibodies is not explained by differences in their ability to fix complement to Pn. As shown by the experiments with purified components of the classic pathway, anticapsular IgG was no better at mediating the formation of a classical pathway C3 convertase than anticell wall IgG. IgG antibodies may affect the rate of alternative pathway activation (46) and, theoretically, anticapsular IgG might lead to greater alternative pathway-mediated amplification of C3 deposition than anticell wall IgG. However, the anticapsular IgG was no better at mediating complement activation in guinea pig serum when both the classic and alternative pathways were present than the anticell wall IgG.
Although the opsonic anticapsular antibodies were totally dependent on complement activation to achieve an in vivo effect, the difference between opsonic and nonopsonic antibodies in their effect on phagocytosis could not be explained by differences in their ability to activate complement or fix C3 to the Pn. Therefore, we hypothesized that complement fixed to the surface of Pn by anticell wall IgG was less readily available to the phagocytic cell complement receptors. The results of experiments performed to test the ability of the different antibodies to mediate immune adherence, a phenomenon dependent on the ability of particle-bound C3b to interact with C3b receptors on human E (33, 47) support this idea. At levels of sensitization that led to the deposition of approximately equal numbers of C3b molecules, Pn sensitized with anticapsular antibodies, whether IgG or IgM, were able to cause immune adherence, whereas those sensitized with the anticell wall IgG were not. Thus, the different cellular locations of the antibodies led to deposition of C3b in locations on the Pn that varied in their ability to interact with the E C3b receptor. It has been shown in both chemical (48) and electron microscope studies (49) that the alternative pathway of complement causes C3b deposition on the cell walls of encapsulated organisms. Thus, the important physiologic difference between cell wall-bound and capsular C3b demonstrated in these experiments provides an explanation for the requirement for specific anticapsular antibody in host defense against encapsulated organisms.
These studies on pneumococcal bacteremia suggest a central role for complement activation and for the precise site of C3b fixation in the protective effects of anticapsular antibody in experimental pneumococcal bacteremia. However, it has been observed that the antipneumococcal antibodies of some species, including human, will not activate complement (50) . This conclusion, derived largely from the work of Horsfall and Goodner in the 1930s (51) (52) (53) , is based on data from experiments employing purified capsular polysaccharide, unfractionated immune serum, and insensitive methods to detect complement consumption. Recent studies in our own laboratory, however, using whole organisms and more sensitive techniques for detecting complement fixation, have demonstrated that under these circumstances human antipneumococcal antibodies can, indeed, activate and fix complement (54) . Thus, it is probable that complement plays an equally critical role in the mediation of the protective effect of human anticapsular antibody as we have shown in the experimental model.
